# Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

> **NCT07093411** · EARLY_PHASE1 · RECRUITING · sponsor: **Beijing GoBroad Hospital** · enrollment: 48 (estimated)

## Conditions studied

- B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory

## Interventions

- **BIOLOGICAL:** LUCAR-E9D or LUCAR-E9K cells product

## Key facts

- **NCT ID:** NCT07093411
- **Lead sponsor:** Beijing GoBroad Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-05
- **Primary completion:** 2028-08
- **Final completion:** 2028-12
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-08-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07093411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07093411, "Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07093411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*